Free Trial

Nurix Therapeutics (NRIX) Stock Price, News & Analysis

Nurix Therapeutics logo
$12.73 +0.29 (+2.33%)
Closing price 07/3/2025 03:29 PM Eastern
Extended Trading
$12.73 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Nurix Therapeutics Stock (NASDAQ:NRIX)

Key Stats

Today's Range
$12.27
$12.76
50-Day Range
$9.30
$12.79
52-Week Range
$8.18
$29.56
Volume
279,635 shs
Average Volume
835,600 shs
Market Capitalization
$970.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.18
Consensus Rating
Moderate Buy

Company Overview

Nurix Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

NRIX MarketRank™: 

Nurix Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 2350th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 15 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nurix Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Nurix Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Nurix Therapeutics are expected to decrease in the coming year, from ($2.99) to ($3.01) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nurix Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nurix Therapeutics is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nurix Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nurix Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    20.45% of the float of Nurix Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nurix Therapeutics has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nurix Therapeutics has recently increased by 2.48%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Nurix Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Nurix Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.45% of the float of Nurix Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nurix Therapeutics has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Nurix Therapeutics has recently increased by 2.48%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Nurix Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Nurix Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    7 people have searched for NRIX on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $137,096.00 in company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of Nurix Therapeutics is held by insiders.

  • Read more about Nurix Therapeutics' insider trading history.
Receive NRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NRIX Stock News Headlines

What is HC Wainwright's Forecast for NRIX FY2026 Earnings?
Nurix Therapeutics (NRIX) to Release Earnings on Thursday
Post-Halving = Profit Season (Here’s How to Win It)
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
Nurix Therapeutics, Inc. (NRIX) - Yahoo Finance
NRIX Nurix Therapeutics, Inc. - Seeking Alpha
See More Headlines

NRIX Stock Analysis - Frequently Asked Questions

Nurix Therapeutics' stock was trading at $18.84 at the beginning of 2025. Since then, NRIX stock has decreased by 32.4% and is now trading at $12.73.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced its quarterly earnings data on Tuesday, April, 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.05. The business earned $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative net margin of 369.40% and a negative trailing twelve-month return on equity of 47.49%.

Nurix Therapeutics (NRIX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager.

Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD) and Visa (V).

Company Calendar

Last Earnings
4/08/2025
Today
7/04/2025
Next Earnings (Estimated)
7/10/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NRIX
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.18
High Stock Price Target
$41.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+137.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
18 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$193.57 million
Net Margins
-369.40%
Pretax Margin
-369.08%

Debt

Sales & Book Value

Annual Sales
$54.55 million
Price / Cash Flow
N/A
Book Value
$7.44 per share
Price / Book
1.71

Miscellaneous

Free Float
70,595,000
Market Cap
$970.54 million
Optionable
Optionable
Beta
2.15
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NRIX) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners